Abstract
Because of the broad neutralization and in vivo protection across influenza A and influenza B virus strains, monoclonal antibody CR9114 is widely used in influenza virus research as a positive control in many experiments. To produce amounts sufficient for the demand requires regular transient transfections, resulting in varying yield as well as differing batch to batch quality. Here, we report the development of a serum-free CHO DG44 cell line, stably producing a CR9114-like antibody with a potential to become a useful influenza virus research tool.
Highlights
Monoclonal antibody CR9114 was first reported by Dreyfus et al in 2012 in a study describing broadly neutralizing human antibodies against influenza B virus strains [1]
Chinese hamster ovary (CHO) DG44 cells were cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s F12 medium supplemented with 10% FBS for 15 passages before the start of the adaptation to serum-free conditions
As the FBS concentration was lowered to 2%, the DMEM/Ham’s F12 medium was supplemented as described above and in parallel ProCHO5, CD DG44, OptiCHO, and CHO-S-SFM II media were tested (Fig 1)
Summary
Monoclonal antibody (mAb) CR9114 was first reported by Dreyfus et al in 2012 in a study describing broadly neutralizing human antibodies against influenza B virus strains [1]. What made this antibody so unique is its ability to bind to group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, HL17, HL18) and group 2 (H3, H4, H7, H10, H14, H15) influenza A virus hemagglutinins (HA) in addition to influenza B HA by interacting with a highly conserved epitope in the stalk region of HA.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
